Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors

References

• Supuran CT, Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nature Rev Drug Discov. 2008;7:168–181.
   PubMed Web of Science ®Google Scholar
• Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nature Rev Drug Discov. 2011;10:767–777.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: from biomedical applications of the inhibitors and activators to biotechnological use for CO(2) capture. J Enzyme Inhib Med Chem. 2013;28:229–230.
   PubMed Web of Science ®Google Scholar
• Smeulders MJ, Barends TR, Pol A, et al. Evolution of a new enzyme for carbon disulphide conversion by an acido-thermophilic archaeon. Nature. 2011;478:412–416.
   PubMed Web of Science ®Google Scholar
• Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem. 2016;31. in press. doi:10.3109/14756366.2015.1122001.
   Google Scholar
• Briganti F, Mangani S, Scozzafava A, et al. Carbonic anhydrase catalyzes cyanamide hydration to urea: is it mimicking the physiological reaction? J Biol Inorg Chem. 1999;4:528–536.
   PubMed Web of Science ®Google Scholar
• Arechederra RL, Waheed A, Sly WS, et al. Effect of sulfonamides as carbonic anhydrase VA and VB inhibitors on mitochondrial metabolic energy conversion. Bioorg Med Chem. 2013;21:1544–1548.
   PubMed Web of Science ®Google Scholar
• De Simone G, Di Fiore A, Supuran CT. Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs? Curr Pharm Des. 2008;14:655–660.
   PubMed Web of Science ®Google Scholar
• Hirohashi N, Alvarez L, Shiba K, et al. Sperm from sneaker male squids exhibit chemotactic swarming to CO2. Curr Biol. 2013;23:775–781.
   PubMed Web of Science ®Google Scholar
• Rummer JL, McKenzie DJ, Innocenti A, et al. Root effect hemoglobin may have evolved to enhance general tissue oxygen delivery. Science. 2013;340:1327–1329.
   PubMed Web of Science ®Google Scholar
• Schlicker C, Hall RA, Vullo D, et al. Structure and inhibition of the CO2-sensing carbonic anhydrase Can2 from the pathogenic fungus Cryptococcus neoformans. J Mol Biol. 2009;385:1207–1220.
   PubMed Web of Science ®Google Scholar
• Capasso C, Supuran CT. An overview of the alpha-, beta- and gamma-carbonic anhydrases from bacteria: can bacterial carbonic anhydrases shed new light on evolution of bacteria? J Enzyme Inhib Med Chem. 2015;30:325–332.
   PubMed Web of Science ®Google Scholar
• Capasso C, Supuran CT. Sulfa and trimethoprim-like drugs – antimetabolites acting as carbonic anhydrase, dihydropteroate synthase and dihydrofolate reductase inhibitors. J Enzyme Inhib Med Chem. 2014;29:379–387.
   PubMed Web of Science ®Google Scholar
• Cottier F, Leewattanapasuk W, Kemp LR, et al. Carbonic anhydrase regulation and CO2 sensing in the fungal pathogen Candida glabrata involves a novel Rca1p ortholog. Bioorg Med Chem. 2013;21:1549–1554.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Capasso C. The η-class carbonic anhydrases as drug targets for antimalarial agents. Expert Opin Ther Targets. 2015;19:551–563.
   PubMed Web of Science ®Google Scholar
• Del Prete S, Vullo D, Fisher GM, et al. Discovery of a new family of carbonic anhydrases in the malaria pathogen Plasmodium falciparum– The η-carbonic anhydrases. Bioorg Med Chem Lett. 2014;24:4389–4396.
   PubMed Web of Science ®Google Scholar
• Xu Y, Feng L, Jeffrey PD, et al. Structure and metal exchange in the cadmium carbonic anhydrase of marine diatoms. Nature. 2008;452:56–61.
   PubMed Web of Science ®Google Scholar
• Alterio V, Di Fiore A, D’Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev. 2012;112:4421–4468.
   PubMed Web of Science ®Google Scholar
• Carta F, Supuran CT. Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005–2013). Expert Opin Ther Pat. 2013;23:681–691.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem. 2012;27:759–772.
   PubMed Web of Science ®Google Scholar
• Carta F, Supuran CT, Scozzafava A. Novel therapies for glaucoma: a patent review 2007–2011. Expert Opin Ther Pat. 2012;22:79–88.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Mincione F, Somma T, et al. A new approach to antiglaucoma drugs: carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology. J Enzyme Inhib Med Chem. 2012;27:138–147.
   PubMed Web of Science ®Google Scholar
• Masini E, Carta F, Scozzafava A, et al. Antiglaucoma carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat. 2013;23:705–716.
   PubMed Web of Science ®Google Scholar
• Thiry A, Dognè JM, Masereel B, et al. Carbonic anhydrase inhibitors as anticonvulsant agents. Curr Top Med Chem. 2007;7:855–864.
   PubMed Web of Science ®Google Scholar
• Thiry A, Dognè JM, Supuran CT, et al. Anticonvulsant sulfonamides/sulfamates/sulfamides with carbonic anhydrase inhibitory activity: drug design and mechanism of action. Curr Pharm Des. 2008;14:661–671.
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Supuran CT, Carta F. Antiobesity carbonic anhydrase inhibitors: a literature and patent review. Expert Opin Ther Pat. 2013;23:725–735.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2012;17:11–15.
   PubMed Web of Science ®Google Scholar
• Supuran CT. The safety and clinical efficacy of acetazolamide for the treatment of idiopathic intracranial hypertension. Expert Rev Neurother. 2015;15:851–856.
   PubMed Web of Science ®Google Scholar
• Monti SM, Supuran CT, De Simone G. Anticancer carbonic anhydrase inhibitors: a patent review (2008–2013). Expert Opin Ther Pat. 2013;23:737–749.
   PubMed Web of Science ®Google Scholar
• Lock FE, McDonald PC, Lou Y, et al. Targeting carbonic anhydrase IX depletes breast cancer stem cell within the hypoxic niche. Oncogene. 2013;32:5210–5219.
   PubMed Web of Science ®Google Scholar
• Carta F, Di Cesare Mannelli L, Pinard M, et al. A class of sulfonamide carbonic anhydrase inhibitors with neuropathic pain modulating effects. Bioorg Med Chem. 2015;23:1828–1840.
   PubMed Web of Science ®Google Scholar
• Di Cesare Mannelli L, Micheli L, Carta F, et al. Carbonic anhydrase inhibition for the management of cerebral ischemia: in vivo evaluation of sulfonamide and coumarin inhibitors. J Enzyme Inhib Med Chem. 2016; doi:10.3109/14756366.2015.1113407). in press.
   Google Scholar
• Luks AM, Swenson ER. Medication and dosage considerations in the prophylaxis and treatment of high-altitude illness. Chest. 2008;133:744–755.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Casini A, Mastrolorenzo A, et al. COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents. Mini Rev Med Chem. 2004;4:625–632.
   PubMed Web of Science ®Google Scholar
• Maresca A, Temperini C, Vu H, et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc. 2009;131:3057–3062.
   PubMed Web of Science ®Google Scholar
• Carta F, Temperini C, Innocenti A, et al. Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010;53:5511–5522.
   PubMed Web of Science ®Google Scholar
• Maresca A, Carta F, Vullo D, et al. Dithiocarbamates strongly inhibit the β-class carbonic anhydrases from Mycobacterium tuberculosis. J Enzyme Inhib Med Chem. 2013;28:407–411.
   PubMed Web of Science ®Google Scholar
• Skarke C, Alamuddin N, Lawson JA, et al. Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649. Clin Pharmacol Ther. 2012;91:986–993.
   PubMed Web of Science ®Google Scholar
• Oosterwijk-Wakka JC, De Weijert MC, Franssen GM, et al. Successful combination of sunitinib and girentuximab in two renal cell carcinoma animal models: a rationale for combination treatment of patients with advanced RCC. Neoplasia. 2015;17:215–224.
   PubMed Web of Science ®Google Scholar
• Pacchiano F, Carta F, McDonald PC, et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem. 2011;54:1896–1902.
   PubMed Web of Science ®Google Scholar
• Kassamali R, Sica DA. Acetazolamide: a forgotten diuretic agent. Cardiol Rev. 2011;19:276–278.
   PubMed Web of Science ®Google Scholar
• Prieto De Paula JM, Villamandos NV, Cancelo SP, et al. Efficacy of acetazolamide treatment of patients with hypercapnia and superimposed metabolic alkalosis. Rev Clin Esp. 1997;197:237–240.
   PubMed Web of Science ®Google Scholar
• Anderson CJ, Kaufman PL, Sturm RJ. Toxicity of combined therapy with carbonic anhydrase inhibitors and aspirin. Am J Ophthalmol. 1978;86:516–519.
   PubMed Web of Science ®Google Scholar
• Hazouard E, Grimbert M, Jonville-Berra AP, et al. Salicylism and glaucoma: reciprocal augmentation of the toxicity of acetazolamide and acetylsalicylic acid. J Fr Ophtalmol. 1999;22:73–75.
   PubMed Web of Science ®Google Scholar
• Cappon GD, Fleeman TL, Cook JC, et al. Combined treatment potentiates the developmental toxicity of ibuprofen and acetazolamide in rats. Drug Chem Toxicol. 2005;28:409–421.
   PubMed Web of Science ®Google Scholar
• Yablonski ME, Maren TH, Hayashi M, et al. Enhancement of the ocular hypotensive effect of acetazolamide by diflunisal. Am J Ophthalmol. 1988;106:332–336.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides. Curr Pharm Des. 2008;14:641–648.
   PubMed Web of Science ®Google Scholar
• Sato J, Nioka M, Owada E, et al. Effect of acetazolamide on the anticonvulsant potency of several antiepileptic drugs in mice. J Pharmacobiodyn. 1983;6:295–300.
   PubMedGoogle Scholar
• Sato J, Nioka M, Owada E, et al. Effect of acetazolamide on the anticonvulsant potency of phenobarbital in mice. J Pharmacobiodyn. 1981;4:952–960.
   PubMedGoogle Scholar
• Burns TG, Lee GP, McCormick ML, et al. Carbonic anhydrase-inhibiting medications and the intracarotid amobarbital procedure in children. Epilepsy Behav. 2009;15:240–244.
   PubMed Web of Science ®Google Scholar
• Bookheimer S, Schrader LM, Rausch R, et al. Reduced anesthetization during the intracarotid amobarbital (Wada) test in patients taking carbonic anhydrase-inhibiting medications. Epilepsia. 2005;46:236–243.
   PubMed Web of Science ®Google Scholar
• Tabbara KF, Al-Faisal Z, Al-Rashed W. Interaction between acetazolamide and cyclosporine. Arch Ophthalmol. 1998;116:832–833.
   PubMedGoogle Scholar
• Ruokoniemi P, Tertti R, Paalosmaa-Puusa P, et al. Acetazolamide may provoke cyclosporine toxicity – a case report. NDT Plus. 2009;2:298–299.
   PubMedGoogle Scholar
• Fujii K, Iranami H, Hatano Y. Exacerbation of acetazolamide-responsive sodium channel myotonia by uterotonic agents. Int J Obstet Anesth. 2011;20:76–79.
   PubMed Web of Science ®Google Scholar
• Carmignani M, Scoppetta C, Ranelletti FO, et al. Adverse interaction between acetazolamide and anticholinesterase drugs at the normal and myasthenic neuromuscular junction level. Int J Clin Pharmacol Ther Toxicol. 1984;22:140–144.
   PubMed Web of Science ®Google Scholar
• Sweeney KR, Chapron DJ, Brandt JL, et al. Toxic interaction between acetazolamide and salicylate: case reports and a pharmacokinetic explanation. Clin Pharmacol Ther. 1986;40:518–524.
   PubMed Web of Science ®Google Scholar
• Hill JB. Experimental salicylate poisoning: observations on the effects of altering blood pH on tissue and plasma salicylate concentrations. Pediatrics. 1971;47:658–665.
   PubMed Web of Science ®Google Scholar
• Innocenti A, Vullo D, Scozzafava A, et al. Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I – XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008;16:7424–7428.
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Mastrolorenzo A, Supuran CT. Carbonic anhydrase inhibitors and activators and their use in therapy. Expert Opin Ther Pat. 2006;16:1627–1664.
   Web of Science ®Google Scholar
• Scott WJ, Duggan CA, Schreiner CM, et al. Reduction of embryonic intracellular pH: a potential mechanism of acetazolamide-induced limb malformations. Toxicol Appl Pharmacol. 1990;103:238–254.
   PubMed Web of Science ®Google Scholar
• Bell SM, Schreiner CM, Resnick E, et al. Exacerbation of acetazolamide teratogenesis by amiloride and its analogs active against Na+/H+ exchangers and Na+ channels. Reprod Toxicol. 1997;11:823–831.
   PubMed Web of Science ®Google Scholar
• Asiedu M, Ossipov MH, Kaila K, et al. Acetazolamide and midazolam act synergistically to inhibit neuropathic pain. Pain. 2010;148:302–308.
   PubMed Web of Science ®Google Scholar
• Araie M, Kitazawa Y, Azuma I, et al. The efficacy and safety of dose escalation of dorzolamide used in combination with other topical antiglaucoma agents. J Ocul Pharmacol Ther. 2003;19:517–525.
   PubMed Web of Science ®Google Scholar
• Asahi MG, Bobarnac Dogaru GL, Onishi SM, et al. Strong topical steroid, NSAID, and carbonic anhydrase inhibitor cocktail for treatment of cystoid macular edema. Int Med Case Rep J. 2015;8:305–312.
   PubMedGoogle Scholar
• Milburn-McNulty P, Powell G, Sills GJ, et al. Sulthiame add-on therapy for epilepsy. Cochrane Database Syst Rev. 2015 Oct 28;10:CD009472. doi:10.1002/14651858.CD009472
   PubMed Web of Science ®Google Scholar
• Bialer M, Doose DR, Murthy B, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet. 2004;43:763–780.
   PubMed Web of Science ®Google Scholar
• Leppik IE. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004;13(Suppl 1):S5–9.
   PubMed Web of Science ®Google Scholar
• Sachdeo RC. Topiramate. Clinical profile in epilepsy. Clin Pharmacokinet. 1998;34:335–346.
   PubMed Web of Science ®Google Scholar
• Casini A, Antel J, Abbate F, et al. Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg Med Chem Lett. 2003;13:841–845.
   PubMed Web of Science ®Google Scholar
• Knudsen JF, Sokol GH, Flowers CM. Adjunctive topiramate enhances the risk of hypothermia associated with valproic acid therapy. J Clin Pharm Ther. 2008;33:513–519.
   PubMed Web of Science ®Google Scholar
• Abraham G, Owen J. Topiramate can cause lithium toxicity. J Clin Psychopharmacol. 2004;24:565–567.
   PubMed Web of Science ®Google Scholar
• Yap KY, Chui WK, Chan A. Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther. 2008;30:1385–1407.
   PubMed Web of Science ®Google Scholar
• Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother. 2010;10:119–140.
   PubMed Web of Science ®Google Scholar
• De Simone G, Di Fiore A, Menchise V, et al. Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett. 2005;15:2315–2320.
   PubMed Web of Science ®Google Scholar
• Weber A, Casini A, Heine A, et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2 selective Celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem. 2004;47:550–557.
   PubMed Web of Science ®Google Scholar
• Di Fiore A, Pedone C, D’Ambrosio K, et al. Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related, cyclooxygenase II “selective” inhibitor celecoxib. Bioorg Med Chem Lett. 2006;16:437–442.
   PubMed Web of Science ®Google Scholar
• Werner U, Werner D, Rau T, et al. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther. 2003;74:130–137.
   PubMed Web of Science ®Google Scholar
• El-Awady RA, Saleh EM, Ezz M, et al. Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells. Toxicol Appl Pharmacol. 2011;255:271–286.
   PubMed Web of Science ®Google Scholar
• Maeda A, Tsuruoka S, Ushijima K, et al. Drug interaction between celecoxib and methotrexate in organic anion transporter 3-transfected renal cells and in rats in vivo. Eur J Pharmacol. 2010;640:168–171.
   PubMed Web of Science ®Google Scholar
• Phelan KM, Mosholder AD, Lu S. Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. J Clin Psychiatry. 2003;64:1328–1334.
   PubMed Web of Science ®Google Scholar
• Fisher AA, Le Couteur DG. Intracerebral hemorrhage following possible interaction between celecoxib and clopidogrel. Ann Pharmacother. 2001;35:1567–1569.
   PubMed Web of Science ®Google Scholar
• Audia P, Feinfeld DA, Dubrow A, et al. Metformin-induced lactic acidosis and acute pancreatitis precipitated by diuretic, celecoxib, and candesartan-associated acute kidney dysfunction. Clin Toxicol (Phila). 2008;46:164–166.
   PubMed Web of Science ®Google Scholar
• Baciewicz AM, Chrisman CR, Finch CK, et al. Update on rifampin and rifabutin drug interactions. Am J Med Sci. 2008;335:126–136.
   PubMed Web of Science ®Google Scholar
• Ruzov M, Rimon G, Pikovsky O, et al. Celecoxib interferes to a limited extent with aspirin-mediated inhibition of platelets aggregation. Br J Clin Pharmacol. 2015; doi:10.1111/bcp.12801. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Youn Choi H, Jin SJ, Jung JA, et al. Effects of ketoconazole on the pharmacokinetic properties of CG100649, a novel NSAID: a randomized, open-label crossover study in healthy Korean male volunteers. Clin Ther. 2014;36:115–125.
   PubMed Web of Science ®Google Scholar
• Ebbesen P, Pettersen EO, Gorr TA, et al. Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies. J Enzyme Inhib Med Chem. 2009;24(Suppl 1):1–39.
   PubMed Web of Science ®Google Scholar
• Pettersen EO, Ebbesen P, Gieling RG, et al. Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. J Enzyme Inhib Med Chem. 2015;30:689–721.
   PubMed Web of Science ®Google Scholar
• Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 2011;71:3364–3376.
   PubMed Web of Science ®Google Scholar
• Touisni N, Maresca A, McDonald PC, et al. Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors. J Med Chem. 2011;54:8271–8277.
   PubMed Web of Science ®Google Scholar
• Muselaers CH, Stillebroer AB, Desar IM, et al. Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma. J Nucl Med. 2014;55:242–247.
   PubMed Web of Science ®Google Scholar
• Gieling RG, Parker CA, De Costa LA, et al. Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells in vitro. J Enzyme Inhib Med Chem. 2013;28:360–369.
   PubMed Web of Science ®Google Scholar
• Swenson ER. Safety of carbonic anhydrase inhibitors. Expert Opin Drug Saf. 2014;13:459–472.
   PubMed Web of Science ®Google Scholar
• Morgan PE, Supuran CT, Casey JR. Carbonic anhydrase inhibitors that directly inhibit anion transport by the human Cl−/HCO3− exchanger, AE1. Mol Membr Biol. 2004;21:423–433.
   PubMed Web of Science ®Google Scholar
• Casey JR, Morgan PE, Vullo D, et al. Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX. J Med Chem. 2004;47:2337–2347.
   PubMed Web of Science ®Google Scholar
• Alvarez BV, Johnson DE, Sowah D, et al. Carbonic anhydrase inhibition prevents and reverts cardiomyocyte hypertrophy. J Physiol. 2007;579:127–145.
   PubMed Web of Science ®Google Scholar
• Bonneau A, Maresca A, Winum JY, et al. Metronidazole-coumarin conjugates and 3-cyano-7-hydroxy-coumarin act as isoform-selective carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem. 2013;28:397–401.
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Carta F, Supuran CT. Secondary and tertiary sulfonamides: a patent review (2008–2012). Expert Opin Ther Pat. 2013;23:203–213.
   PubMed Web of Science ®Google Scholar
• De Simone G, Alterio V, Supuran CT. Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors. Expert Opin Drug Discov. 2013;8:793–810.
   PubMed Web of Science ®Google Scholar
• Bayram E, Senturk M, Kufrevioglu OI, et al. In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II. Bioorg Med Chem. 2008;16:9101–9105.
   PubMed Web of Science ®Google Scholar
• Şentürk M, Gülçin I, Daştan A, et al. Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. Bioorg Med Chem. 2009;17:3207–3211.
   PubMed Web of Science ®Google Scholar
• Sonmez F, Gençer N, Bilen Ç, et al. In vitro inhibition effect and structure-activity relationships of some saccharin derivatives on erythrocyte carbonic anhydrase I and II. J Enzyme Inhib Med Chem. 2014;29:118–123.
   PubMed Web of Science ®Google Scholar
• Karataş MO, Uslu H, Sarı S, et al. Coumarin or benzoxazinone based novel carbonic anhydrase inhibitors: synthesis, molecular docking and anticonvulsant studies. J Enzyme Inhib Med Chem. 2016;31. in press. doi:10.3109/14756366.2015.1063624
   Web of Science ®Google Scholar